Crohn Disease Clinical Trials in New York, New York

10 studies are recruiting for crohn disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

   Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in …

   Stage

   Phase 3

   Ages

   Any age

   Site

   New York Gastroenterology Associates ( Site 0253), New York, New York

   Locations

   37 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06651281 on ClinicalTrials.gov

3. Standardized Microbiota Transplant Therapy in Crohn's Disease

   Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation …

   Stage

   Phase 2

   Ages

   18 to 89

   Site

   NYU Langone Health, New York, New York

   Locations

   3 in total

   Run by

   University of Minnesota

   See if you can join NCT06631586 on ClinicalTrials.gov

4. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Inflammatory Bowel Disease Center at NYU Langone, New York, New York

   Locations

   370 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07196722 on ClinicalTrials.gov

5. A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Gastroenterology Associates, New York, New York

   Locations

   160 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07499232 on ClinicalTrials.gov

6. A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intesti…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Gastroenterology Associates, New York, New York

   Locations

   142 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07577843 on ClinicalTrials.gov

7. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

   The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Locations

   24 in total

   Run by

   Mayo Clinic

   See if you can join NCT05230173 on ClinicalTrials.gov

8. Low Dose IL-2 for the Treatment of Crohn's Disease

   The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.

   Stage

   Phase 1

   Ages

   12 to 80

   Site

   Mount Sinai, New York, New York

   Locations

   3 in total

   Run by

   Boston Children's Hospital

   See if you can join NCT04263831 on ClinicalTrials.gov

9. Autologous Stem Cell Transplant for Crohn's Disease

   Crohn's Disease (CD) is an inflammatory bowel disease. It can lead to significant complications and discomfort in the stomach and intestines. Crohn's disease is a debilitating, incurable disease of immune cells; it affects almost 1 million people in the United States. CD is characterized by inflamm…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Aaron Etra

   See if you can join NCT03219359 on ClinicalTrials.gov

10. Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

    Crohn's disease (CD) is a condition that causes inflammation (swelling, redness) of the lining and wall of the small intestine, large intestine, or both. CD may be associated with abdominal cramps/pain, diarrhea, blood in the stool, weight loss, or delayed growth in children. While the exact cause …

    Stage

    Phase 4

    Ages

    6 to 17

    Site

    Columbia University Medical Center, New York, New York

    Locations

    26 in total

    Run by

    Connecticut Children's Medical Center

    See if you can join NCT05781152 on ClinicalTrials.gov